;PMID: 8490179
;source_file_779.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:38..112] = [t:38..112]
;2)section:[e:116..208] = [t:116..208]
;3)section:[e:212..290] = [t:212..290]
;4)sentence:[e:294..387] = [t:294..387]
;5)sentence:[e:388..596] = [t:388..596]
;6)sentence:[e:597..643] = [t:597..643]
;7)sentence:[e:644..737] = [t:644..737]
;8)sentence:[e:738..899] = [t:738..899]
;9)sentence:[e:900..1005] = [t:900..1005]
;10)sentence:[e:1006..1146] = [t:1006..1146]
;11)sentence:[e:1147..1293] = [t:1147..1293]
;12)sentence:[e:1294..1456] = [t:1294..1456]
;13)section:[e:1460..1504] = [t:1460..1504]

;section 0 Span:0..33
;Blood  1993 May 15;81(10):2708-13
(SEC
  (FRAG (NNP:[0..5] Blood) (CD:[7..11] 1993) (NNP:[12..15] May) (CD:[16..18] 15)
        (CC:[18..22] ;81-LRB-) (CD:[22..24] 10) (-RRB-:[24..25] -RRB-)
        (CD:[25..30] :2708) (::[30..31] -) (CD:[31..33] 13)))

;sentence 1 Span:38..112
;Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
;[63..65]...[72..75]:gene-rna:"N-"..."ras"
;[70..75]:gene-rna:"K-ras"
;[89..111]:malignancy:"plasma cell dyscrasias"
(SENT
  (NP-HLN
    (NP (JJ:[38..48] Mutational) (NN:[49..59] activation))
    (PP (IN:[60..62] of)
      (NP
        (NP
          (NML (NN:[63..64] N) (HYPH:[64..65] -)
            (NML-1 (-NONE-:[65..65] *P*)))
          (NML-2 (-NONE-:[65..65] *P*)))
        (CC:[66..69] and)
        (NP
          (NML (NN:[70..71] K) (HYPH:[71..72] -)
            (NML-1 (NN:[72..75] ras)))
          (NML-2 (NNS:[76..85] oncogenes)))))
    (PP-LOC (IN:[86..88] in)
      (NP (NN:[89..95] plasma) (NN:[96..100] cell) (NNS:[101..111] dyscrasias)))
    (.:[111..112] .)))

;section 2 Span:116..208
;Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM,
;Boccadoro  M, Pileri A.
(SEC
  (FRAG (NNP:[116..125] Corradini) (NNP:[126..127] P) (,:[127..128] ,)
        (NNP:[129..136] Ladetto) (NNP:[137..139] M,) (NNP:[140..145] Voena)
        (NNP:[146..147] C) (,:[147..148] ,) (NNP:[149..156] Palumbo)
        (NNP:[157..158] A) (,:[158..159] ,) (NNP:[160..169] Inghirami)
        (NNP:[170..171] G) (,:[171..172] ,) (NNP:[173..180] Knowles)
        (NNP:[181..183] DM) (,:[183..184] ,) (NNP:[185..194] Boccadoro)
        (NNP:[196..198] M,) (NNP:[199..205] Pileri) (NN:[206..208] A.)))

;section 3 Span:212..290
;Department of Medicine and Experimental Oncology, University of Torino,
;Italy.
(SEC
  (FRAG (NNP:[212..222] Department) (IN:[223..225] of) (NNP:[226..234] Medicine)
        (CC:[235..238] and) (NNP:[239..251] Experimental)
        (NNP:[252..260] Oncology) (,:[260..261] ,) (NNP:[262..272] University)
        (IN:[273..275] of) (NNP:[276..282] Torino) (,:[282..283] ,)
        (NNP:[284..289] Italy) (.:[289..290] .)))

;sentence 4 Span:294..387
;The frequency of N- and K-ras oncogene mutations was investigated in plasma
;cell  dyscrasias.
;[311..313]...[320..323]:gene-rna:"N-"..."ras"
;[318..323]:gene-rna:"K-ras"
;[363..386]:malignancy:"plasma cell  dyscrasias"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[294..297] The) (NN:[298..307] frequency))
      (PP (IN:[308..310] of)
        (NP
          (NP
            (NML (NN:[311..312] N) (HYPH:[312..313] -)
              (NML-2 (-NONE-:[313..313] *P*)))
            (NML-1 (-NONE-:[313..313] *P*)))
          (CC:[314..317] and)
          (NP
            (NML (NN:[318..319] K) (HYPH:[319..320] -)
              (NML-2 (NN:[320..323] ras)))
            (NML-1 (NN:[324..332] oncogene) (NNS:[333..342] mutations))))))
    (VP (VBD:[343..346] was)
      (VP (VBN:[347..359] investigated)
        (NP-3 (-NONE-:[359..359] *))
        (PP-LOC (IN:[360..362] in)
          (NP (NN:[363..369] plasma) (NN:[370..374] cell)
              (NNS:[376..386] dyscrasias)))))
    (.:[386..387] .)))

;sentence 5 Span:388..596
;Genomic DNAs from 128 patients were selected for this study: 30  monoclonal
;gammopathies of undetermined significance, 8 solitary plasmacytomas,  77
;multiple myelomas (MM), and 13 plasma cell leukemias (PCL).
;[453..476]:malignancy:"monoclonal gammopathies"
;[509..531]:malignancy:"solitary plasmacytomas"
;[537..554]:malignancy:"multiple myelomas"
;[556..558]:malignancy:"MM"
;[568..589]:malignancy:"plasma cell leukemias"
;[591..594]:malignancy:"PCL"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (JJ:[388..395] Genomic) (NNS:[396..400] DNAs))
        (PP (IN:[401..405] from)
          (NP (CD:[406..409] 128) (NNS:[410..418] patients))))
      (NP-2 (-NONE-:[418..418] *ICH*)))
    (VP (VBD:[419..423] were)
      (VP (VBN:[424..432] selected)
        (NP-1 (-NONE-:[432..432] *))
        (PP (IN:[433..436] for)
          (NP (DT:[437..441] this) (NN:[442..447] study)))
        (::[447..448] :)
        (NP-2
          (NP
            (NP (CD:[449..451] 30)
               (JJ:[453..463] monoclonal) (NNS:[464..476] gammopathies))
            (PP (IN:[477..479] of)
              (NP (JJ:[480..492] undetermined) (NN:[493..505] significance))))
          (,:[505..506] ,)
          (NP (CD:[507..508] 8)
             (JJ:[509..517] solitary) (NNS:[518..531] plasmacytomas))
          (,:[531..532] ,)
          (NP (CD:[534..536] 77)
            (NML
              (NML (JJ:[537..545] multiple) (NNS:[546..554] myelomas))
              (NML (-LRB-:[555..556] -LRB-) (NN:[556..558] MM)
                   (-RRB-:[558..559] -RRB-))))
          (,:[559..560] ,) (CC:[561..564] and)
          (NP (CD:[565..567] 13)
            (NML
              (NML (NN:[568..574] plasma) (NN:[575..579] cell)
                   (NNS:[580..589] leukemias))
              (NML (-LRB-:[590..591] -LRB-) (NN:[591..594] PCL)
                   (-RRB-:[594..595] -RRB-)))))))
    (.:[595..596] .)))

;sentence 6 Span:597..643
;A two-step  experimental approach was devised.
(SENT
  (S
    (NP-SBJ-1 (DT:[597..598] A)
      (NML (CD:[599..602] two) (HYPH:[602..603] -) (NN:[603..607] step))
      (JJ:[609..621] experimental) (NN:[622..630] approach))
    (VP (VBD:[631..634] was)
      (VP (VBN:[635..642] devised)
        (NP-1 (-NONE-:[642..642] *))))
    (.:[642..643] .)))

;sentence 7 Span:644..737
;All samples were screened for mutations by  single-strand conformation
;polymorphism analysis.
;[674..683]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ-1 (DT:[644..647] All) (NNS:[648..655] samples))
    (VP (VBD:[656..660] were)
      (VP (VBN:[661..669] screened)
        (NP-1 (-NONE-:[669..669] *))
        (PP (IN:[670..673] for)
          (NP (NNS:[674..683] mutations)))
        (PP-MNR (IN:[684..686] by)
          (NP
            (NML (JJ:[688..701] single-strand) (NN:[702..714] conformation)
                 (NN:[715..727] polymorphism))
            (NN:[728..736] analysis)))))
    (.:[736..737] .)))

;sentence 8 Span:738..899
;DNA fragments displaying an  altered electrophoretic mobility were further
;studied by direct sequencing to  confirm and characterize the nature of the
;mutations.
;[889..898]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[738..741] DNA) (NNS:[742..751] fragments))
      (VP (VBG:[752..762] displaying)
        (NP (DT:[763..765] an) (JJ:[767..774] altered)
            (JJ:[775..790] electrophoretic) (NN:[791..799] mobility))))
    (VP (VBD:[800..804] were)
      (ADVP (RB:[805..812] further))
      (VP (VBN:[813..820] studied)
        (NP-1 (-NONE-:[820..820] *))
        (PP-MNR (IN:[821..823] by)
          (NP (JJ:[824..830] direct) (NN:[831..841] sequencing)))
        (S-PRP
          (NP-SBJ (-NONE-:[841..841] *))
          (VP (TO:[842..844] to)
            (VP (VB:[846..853] confirm) (CC:[854..857] and)
                (VB:[858..870] characterize)
              (NP
                (NP (DT:[871..874] the) (NN:[875..881] nature))
                (PP (IN:[882..884] of)
                  (NP (DT:[885..888] the) (NNS:[889..898] mutations)))))))))
    (.:[898..899] .)))

;sentence 9 Span:900..1005
;Ras mutations are not  randomly distributed because they are detectable only
;in MM (9%) and PCL  (30.7%).
;[900..903]:gene-rna:"Ras"
;[980..982]:malignancy:"MM"
;[992..995]:malignancy:"PCL"
(SENT
  (S
    (NP-1 (NN:[900..903] Ras) (NNS:[904..913] mutations))
    (VP (VBP:[914..917] are) (RB:[918..921] not)
      (ADVP (RB:[923..931] randomly))
      (VP (VBN:[932..943] distributed)
        (NP-1 (-NONE-:[943..943] *T*))
        (SBAR-PRP (IN:[944..951] because)
          (S
            (NP-SBJ (PRP:[952..956] they))
            (VP (VBP:[957..960] are)
              (ADJP-PRD (JJ:[961..971] detectable))
              (PP
                (ADVP (RB:[972..976] only))
                (IN:[977..979] in)
                (NP
                  (NP (NN:[980..982] MM)
                    (PRN (-LRB-:[983..984] -LRB-)
                      (NP (CD:[984..985] 9) (NN:[985..986] %))
                      (-RRB-:[986..987] -RRB-)))
                  (CC:[988..991] and)
                  (NP (NN:[992..995] PCL)
                    (PRN (-LRB-:[997..998] -LRB-)
                      (NP (CD:[998..1002] 30.7) (NN:[1002..1003] %))
                      (-RRB-:[1003..1004] -RRB-))))))))))
    (.:[1004..1005] .)))

;sentence 10 Span:1006..1146
;N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be  mutated, but
;N-ras codon 61 mutation was the most frequent finding (63.6%).
;[1006..1011]:gene-rna:"N-ras"
;[1012..1022]:variation-location:"codons 12,"
;[1012..1018]...[1031..1033]:variation-location:"codons"..."61"
;[1012..1018]...[1023..1025]:variation-location:"codons"..."13"
;[1038..1043]:gene-rna:"K-ras"
;[1044..1052]:variation-location:"codon 12"
;[1084..1089]:gene-rna:"N-ras"
;[1090..1098]:variation-location:"codon 61"
;[1099..1107]:variation-event:"mutation"
(SENT
  (S
    (S
      (NP-SBJ-3
        (NP
          (NP
            (NML-1 (NN:[1006..1011] N-ras))
            (NML-2 (NNS:[1012..1018] codons))
            (CD:[1019..1021] 12))
          (,:[1021..1022] ,)
          (NP
            (NML-1 (-NONE-:[1022..1022] *P*))
            (NML-2 (-NONE-:[1022..1022] *P*))
            (CD:[1023..1025] 13))
          (,:[1025..1026] ,) (CC:[1027..1030] and)
          (NP
            (NML-1 (-NONE-:[1030..1030] *P*))
            (NML-2 (-NONE-:[1030..1030] *P*))
            (CD:[1031..1033] 61)))
        (CC:[1034..1037] and)
        (NP (NN:[1038..1043] K-ras)
           (NN:[1044..1049] codon) (CD:[1050..1052] 12)))
      (VP (VBD:[1053..1057] were)
        (VP (VBN:[1058..1063] found)
          (S
            (NP-SBJ-3 (-NONE-:[1063..1063] *))
            (VP (TO:[1064..1066] to)
              (VP (VB:[1067..1069] be)
                (VP (JJ:[1071..1078] mutated)
                  (NP-3 (-NONE-:[1078..1078] *)))))))))
    (,:[1078..1079] ,) (CC:[1080..1083] but)
    (S
      (NP-SBJ
        (NML (NN:[1084..1089] N-ras)
           (NN:[1090..1095] codon) (CD:[1096..1098] 61))
        (NN:[1099..1107] mutation))
      (VP (VBD:[1108..1111] was)
        (NP-PRD (DT:[1112..1115] the) (RBS:[1116..1120] most)
                (JJ:[1121..1129] frequent) (NN:[1130..1137] finding))
        (PRN (-LRB-:[1138..1139] -LRB-)
          (NP (CD:[1139..1143] 63.6) (NN:[1143..1144] %))
          (-RRB-:[1144..1145] -RRB-))))
    (.:[1145..1146] .)))

;sentence 11 Span:1147..1293
;In  conclusion, ras mutations were found in PCL, and in a subset of MM
;characterized  by advanced-stage disease and adverse prognostic parameters.
;[1163..1166]:gene-rna:"ras"
;[1191..1194]:malignancy:"PCL"
;[1215..1258]:malignancy:"MM characterized  by advanced-stage disease"
(SENT
  (S
    (PP (IN:[1147..1149] In)
      (NP (NN:[1151..1161] conclusion)))
    (,:[1161..1162] ,)
    (NP-SBJ-1 (NN:[1163..1166] ras) (NNS:[1167..1176] mutations))
    (VP (VBD:[1177..1181] were)
      (VP (VBN:[1182..1187] found)
        (NP-1 (-NONE-:[1187..1187] *))
        (PP
          (PP (IN:[1188..1190] in)
            (NP (NN:[1191..1194] PCL)))
          (,:[1194..1195] ,) (CC:[1196..1199] and)
          (PP (IN:[1200..1202] in)
            (NP
              (NP
                (NP (DT:[1203..1204] a) (NN:[1205..1211] subset))
                (PP (IN:[1212..1214] of)
                  (NP (NN:[1215..1217] MM))))
              (VP (VBN:[1218..1231] characterized)
                (NP (-NONE-:[1231..1231] *))
                (PP (IN:[1233..1235] by)
                  (NP-LGS
                    (NP (JJ:[1236..1250] advanced-stage)
                        (NN:[1251..1258] disease))
                    (CC:[1259..1262] and)
                    (NP (JJ:[1263..1270] adverse) (JJ:[1271..1281] prognostic)
                        (NNS:[1282..1292] parameters))))))))))
    (.:[1292..1293] .)))

;sentence 12 Span:1294..1456
;Furthermore, based  on our findings, it is possible to speculate that ras
;mutations represent a late  molecular lesion in the process of multistep
;carcinogenesis.
;[1364..1367]:gene-rna:"ras"
(SENT
  (S
    (ADVP (RB:[1294..1305] Furthermore))
    (,:[1305..1306] ,)
    (PP (VBN:[1307..1312] based)
      (PP (IN:[1314..1316] on)
        (NP (PRP$:[1317..1320] our) (NNS:[1321..1329] findings))))
    (,:[1329..1330] ,)
    (NP-SBJ
      (NP (PRP:[1331..1333] it))
      (S-1 (-NONE-:[1333..1333] *ICH*)))
    (VP (VBZ:[1334..1336] is)
      (ADJP-PRD (JJ:[1337..1345] possible))
      (S-1
        (NP-SBJ (-NONE-:[1345..1345] *))
        (VP (TO:[1346..1348] to)
          (VP (VB:[1349..1358] speculate)
            (SBAR (IN:[1359..1363] that)
              (S
                (NP-SBJ (NN:[1364..1367] ras) (NNS:[1368..1377] mutations))
                (VP (VBP:[1378..1387] represent)
                  (NP (DT:[1388..1389] a) (JJ:[1390..1394] late)
                      (JJ:[1396..1405] molecular) (NN:[1406..1412] lesion))
                  (PP (IN:[1413..1415] in)
                    (NP
                      (NP (DT:[1416..1419] the) (NN:[1420..1427] process))
                      (PP (IN:[1428..1430] of)
                        (NP (JJ:[1431..1440] multistep)
                            (NN:[1441..1455] carcinogenesis))))))))))))
    (.:[1455..1456] .)))

;section 13 Span:1460..1504
;PMID: 8490179 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1460..1464] PMID) (::[1464..1465] :) (CD:[1466..1473] 8490179)
        (NN:[1474..1475] -LSB-) (NNP:[1475..1481] PubMed) (::[1482..1483] -)
        (NN:[1484..1491] indexed) (IN:[1492..1495] for)
        (NNP:[1496..1504] MEDLINE-RSB-)))
